Nanotherapy delivery of c-myc inhibitor targets Protumor Macrophages and preserves Antitumor Macrophages in Breast Cancer
Alison K. Esser(Washington University in St. Louis), Michael H. Ross(Molecular Oncology (United States)), Francesca Fontana(Molecular Oncology (United States)), Xinming Su(Molecular Oncology (United States)), Ariel Gabay(Washington University in St. Louis), Gregory C. Fox(Washington University in St. Louis), Yalin Xu(Washington University in St. Louis), Jingyu Xiang(Washington University in St. Louis), Anne H. Schmieder(Washington University in St. Louis), Xiaoxia Yang(Washington University in St. Louis), Grace Cui(Washington University in St. Louis), Michael J. Scott(Washington University in St. Louis), Samuel Achilefu(Washington University in St. Louis), Jay Chauhan(University of Maryland, Baltimore), Steven Fletcher(University of Maryland, Baltimore), Gregory M. Lanza(Washington University in St. Louis), Katherine N. Weilbaecher(Washington University in St. Louis)
Cited by 41Open Access
Abstract
These data suggest αvβ3-NP-mediated drug delivery of a c-MYC inhibitor can reduce protumor M2-like macrophages while preserving antitumor M1-like macrophages in breast cancer.
Related Papers
No related papers found
Powered by citation graph analysis